Stay updated with breaking news from Alexandra Balcom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nuvalent (NASDAQ:NUVL – Free Report) had its price target boosted by BMO Capital Markets from $93.00 to $102.00 in a research report report published on Wednesday, Benzinga reports. They currently have an outperform rating on the stock. Several other equities analysts have also recently issued reports on the stock. Robert W. Baird started coverage on […]
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer
(RTTNews) - Nuvalent Inc. (NUVL) reported that its third quarter net loss widened to $33.65 million or $0.59 per share from $19.72 million or $0.4...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...